Company Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands.
In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems.
The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE.
Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
| Country | United States |
| Founded | 1849 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 81,000 |
| CEO | Albert Bourla |
Contact Details
Address: 66 Hudson Boulevard East New York, New York 10001-2192 United States | |
| Phone | 212 733 2323 |
| Website | pfizer.com |
Stock Details
| Ticker Symbol | PFE |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000078003 |
| CUSIP Number | 717081103 |
| ISIN Number | US7170811035 |
| Employer ID | 13-5315170 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Albert Bourla D.V.M., Ph.D. | Chairman of the Board and Chief Executive Officer |
| David M. Denton | Chief Financial Officer and Executive Vice President |
| Dr. Chris Boshoff FMedSci, M.D., Ph.D. | Chief Scientific Officer and President of Research and Development |
| Jennifer B. Damico | Senior Vice President, Controller and Principal Accounting Officer |
| Lidia L. Fonseca | Executive Vice President and Chief Digital and Technology Officer |
| Francesca M. DeMartino | Chief Investor Relations Officer |
| Douglas M. Lankler | Executive Vice President and Chief Legal Officer |
| Payal Sahni Becher | Chief People Experience Officer and Executive Vice President |
| Sally M. Susman | Executive Vice President and Chief Corporate Affairs Officer |
| Dr. Michael S. Vincent M.D., Ph.D. | Senior Vice President and Chief Scientific Officer of Inflammation and Immunology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 5, 2025 | 10-Q | Quarterly Report |
| Aug 5, 2025 | 8-K | Current Report |
| Jun 16, 2025 | 11-K | Annual report of employee stock purchase, savings and similar plans |
| Jun 16, 2025 | 11-K | Annual report of employee stock purchase, savings and similar plans |
| May 30, 2025 | SD | Form - SD |
| May 23, 2025 | 144 | Filing |
| May 20, 2025 | CERT | Certification by an exchange approving securities for listing |
| May 19, 2025 | 8-A12B | Registration of securities |
| May 19, 2025 | 8-K | Current Report |
| May 15, 2025 | 424B5 | Filing |